Activities and time-kill studies of selected penicillins, β-lactamase inhibitor combinations, and glycopeptides against Enterococcus faecalis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 857-861

  Hoellman, Dianne B ^a   Visalli, Melissa A ^a   Jacobs, Michael R ^b   Appelbaum, Peter C ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; BETA LACTAMASE INHIBITOR; GLYCOPEPTIDE; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TEICOPLANIN; TICARCILLIN; TIMENTIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

EID: 0031956288     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.857     Document Type: Article

References (21)

1. Arthur, M., and P. Courvalin. 1993. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob. Agents Chemother. 37:1563-1571.
2. Baron, E. J., and R. N. Jones. 1995. National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn. Microbiol. Infect. Dis. 21:141-151.
3. Coque, T. M., R. C. Arduino, and B. E. Murray. 1995. High-level resistance to aminoglycosides: comparison of community and nosocomial fecal isolates of enterococci. Clin. Infect. Dis. 20:1048-1051.
4. Courvalin, P. 1990. Resistance of enterococci to glycopeptides. Antimicrob. Agents Chemother. 34:2291-2296.
5. Eliopoulos, G. M. 1993. Increasing problems in the therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 12:409-412.
6. Gordon, S., J. M. Swenson, B. C. Hill, N. E. Pigott, R. R. Facklam, R. C. Cooksey, C. Thornsberry, Enterococcal Study Group, W. R. Jarvis, and F. C. Tenover. 1992. Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. J. Clin. Microbiol. 30:2373-2378.
7. Greenwood, D. 1989. Antibiotic resistance in enterococci. J. Antimicrob. Chemother. 24:631-635.
8. Jones, R. N., M. A. Pfaller, P. C. Fuchs, K. Aldridge, S. D. Allen, and E. H. Gerlach. 1989. Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains. Diagn. Microbiol. Infect. Dis. 12:489-494.
9. Klepser, M. E., M. N. Marangos, Z. Zhu, D. P. Nicolau, R. Quintiliani, and C. H. Nightingale. 1997. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:435-439.
10. Leclerq, R., S. Dutka-Malen, J. Duval, and P. Courvalin. 1992. Vancomycin resistance gene vanC is specific to Enterococcus gallinarum. Antimicrob. Agents Chemother. 36:2005-2008.
11. Marshall, S. A., K. E. Aldridge, S. D. Allen, P. C. Fuchs, E. H. Gerlach, and R. N. Jones. 1995. Comparative antimicrobial activity of piperacillin-tazobactam tested against more than 5000 recent clinical isolates from five medical centers. Diagn. Microbiol. Infect. Dis. 21:153-168.
12. Murray, B. E., K. V. Singh, S. M. Markowitz, H. A. Lopardo, J. E. Patterson, M. J. Zervos, E. Rubeglio, G. M. Eliopoulos, L. B. Rice, F. W. Goldstein, S. G. Jenkins, G. M. Caputo, R. Nasnas, L. S. Moore, E. S. Wong, and G. Weinstock. 1991. Evidence for clonal spread of a single strain of ß-lactamase-producing Enterococcus (Streptococcus) faecalis to six hospitals in five states. J. Infect. Dis. 163:780-785.
13. Murray, P. R., H. F. Cantrell, R. B. Lankford, and the In Vitro Susceptibility Surveillance Group. 1994. Multicenter evaluation of the in vitro activity of piperacillin-tazobactam compared with eleven selected ß-lactam antibiotics and ciprofloxacin against more than 42,000 aerobic gram-positive and gramnegative bacteria. Diagn. Microbiol. Infect. Dis. 19:111-120.
14. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
15. Okhuysen, P. C., K. V. Singh, and B. E. Murray. 1993. Susceptibility of ß-lactamase-producing enterococci to piperacillin with tazobactam. Diagn. Microbiol. Infect. Dis. 17:219-224.
16. Oster, S. E., V. A. Chirurgi, A. A. Goldberg, S. Aiken, and R. E. McCabe. 1990. Ampicillin-resistant enterococcal species in an acute-care hospital. Antimicrob. Agents Chemother. 34:1821-1823.
17. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1984. Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology. Antimicrob. Agents Chemother. 38:2065-2072.
18. Patterson, J. E., and M. J. Zervos. 1989. Susceptibility and bactericidal activity studies of four ß-lactamase-producing enterococci. Antimicrob. Agents Chemother. 33:251-253.
19. Patterson, J. E., and M. J. Zervos. 1990. High-level gentamicin resistance in Enterococcus: microbiology, genetic basis, and epidemiology. Rev. Infect. Dis. 12:644-652.
20. Rhinehart, E., N. E. Smith, C. Wennersten, E. Gorss, J. Freeman, G. M. Eliopoulos, R. C. Moellering, Jr., and D. A. Goldmann. 1990. Rapid dissemination of ß-lactamase-producing aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N. Engl. J. Med 323:1814-1818.
21. Rice, L. B., and D. M. Shlaes. 1995. Vancomycin resistance in the enterococcus. Relevance in pediatrics. Pediatr. Clin. N. Am. 42:601-618.